Wong Jenny, Quinn Carmel M, Brown Andrew J
School of Biotechnology and Biomolecular Sciences, Biosciences Building D26, The University of New South Wales, Sydney, NSW 2052, Australia.
Biochem J. 2006 Dec 15;400(3):485-91. doi: 10.1042/BJ20060914.
Cholesterol accumulation and removal are regulated by two different transcription factors. SREBP-2 (sterol-regulatory-element-binding protein-2) is best known to up-regulate genes involved in cholesterol biosynthesis and uptake, whereas LXR (liver X receptor) is best known for up-regulating cholesterol efflux genes. An important cholesterol efflux gene that is regulated by LXR is the ATP-binding cassette transporter, ABCA1 (ATP-binding cassette transporter-A1). We have previously shown that statin treatment down-regulated ABCA1 expression in human macrophages, probably by inhibiting synthesis of the LXR ligand 24(S),25-epoxycholesterol. However, it was subsequently reported that ABCA1 expression is down-regulated by SREBP-2 through binding of SREBP-2 to an E-box element in ABCA1's proximal promoter. As statin treatment induces SREBP-2 activation, this may provide an alternative explanation for the statin-mediated down-regulation of ABCA1. In the present study, we employed a set of CHO (Chinese-hamster ovary) mutant cell lines to investigate the role of SREBP-2 in the regulation of ABCA1. We observed increased ABCA1 mRNA levels in SREBP-2-overexpressing cells and decreased levels in cells lacking a functional SREBP-2 pathway, which were restored when the SREBP-2 pathway was reinstated. Moreover, ABCA1 gene expression was positively associated with synthesis of 24(S),25-epoxycholesterol in these cell lines. In studies using a human ABCA1 promoter reporter assay, mutation of the E-box motif had a similar response as the wild-type construct to either statin treatment or addition of 24(S),25-epoxycholesterol. By contrast, these responses were completely ablated when the DR4 element to which LXR binds was mutated. These results support the idea that 24(S),25-epoxycholesterol and statin treatment influence ABCA1 transcription via supply of an LXR ligand and not through an SREBP-2/E-box-related mechanism. In addition, our results indicate a critical role of SREBP-2 as a positive regulator of ABCA1 gene expression by enabling the generation of oxysterol ligands for LXR.
胆固醇的积累和清除由两种不同的转录因子调控。固醇调节元件结合蛋白2(SREBP - 2)最广为人知的作用是上调参与胆固醇生物合成和摄取的基因,而肝脏X受体(LXR)则以上调胆固醇流出基因而闻名。一种受LXR调控的重要胆固醇流出基因是ATP结合盒转运蛋白ABCA1(ATP结合盒转运蛋白A1)。我们之前已经表明,他汀类药物治疗会下调人类巨噬细胞中ABCA1的表达,可能是通过抑制LXR配体24(S),25 - 环氧胆固醇的合成。然而,随后有报道称,SREBP - 2通过与ABCA1近端启动子中的E - 盒元件结合而下调ABCA1的表达。由于他汀类药物治疗会诱导SREBP - 2激活,这可能为他汀类药物介导的ABCA1下调提供另一种解释。在本研究中,我们使用了一组中国仓鼠卵巢(CHO)突变细胞系来研究SREBP - 2在ABCA1调控中的作用。我们观察到,在过表达SREBP - 2的细胞中ABCA1 mRNA水平升高,而在缺乏功能性SREBP - 2途径的细胞中水平降低,当恢复SREBP - 2途径时,水平恢复。此外,在这些细胞系中,ABCA1基因表达与24(S),25 - 环氧胆固醇的合成呈正相关。在使用人类ABCA1启动子报告基因检测的研究中,E - 盒基序的突变对他汀类药物治疗或添加24(S),25 - 环氧胆固醇的反应与野生型构建体相似。相比之下,当LXR结合的DR4元件发生突变时,这些反应完全消失。这些结果支持这样一种观点,即24(S),25 - 环氧胆固醇和他汀类药物治疗通过提供LXR配体而非通过SREBP - 2/E - 盒相关机制影响ABCA1转录。此外,我们的结果表明,SREBP - 2作为ABCA1基因表达的正调控因子,通过为LXR生成氧化固醇配体而发挥关键作用。